On Aug. 27, 2020, AIM ImmunoTech announced that it had identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

This result supports AIM’s goal of developing an intranasal prophylactic approach using Ampligen to prevent COVID-19.